Royalty Pharma (RPRX) competitors & alternatives
Health Care · NASDAQ
Royalty Pharma (RPRX)'s top competitors and alternatives — its most similar public companies — include Ares Management (ARES), Blackstone Inc. (BX), LIGAND PHARMACEUTICALS INC (LGND), INNOVIVA INC (INVA), ENANTA PHARMACEUTICALS INC (ENTA), XOMA ROYALTY CORP (XOMA), Revvity (RVTY), ZYMEWORKS INC (ZYME), ACHIEVE LIFE SCIENCES INC (ACHV), Halozyme (HALO), SELLAS LIFE SCIENCES GROUP INC (SLS) and IQVIA (IQV). These are Royalty Pharma's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RPRX competitors & alternatives
-
Ares ManagementARESFinancials
A $622 billion alternative asset manager operating four complementary investment groups across credit, private equity, real assets, and secondaries with a…
$119.57 (as of 2026-07-22) · market cap $26.5B
-
Blackstone Inc.BXFinancials
Blackstone is a premier global alternative asset manager providing specialized investment strategies across private equity, real estate, and credit markets for…
$122.82 (as of 2026-07-22) · market cap $149.7B
-
LIGAND PHARMACEUTICALS INCLGNDHealth Care
Ligand Pharmaceuticals is a biotechnology firm that generates recurring revenue through royalty interests and the licensing of proprietary drug formulation…
$304.26 (as of 2026-07-22) · market cap $6.1B
-
INNOVIVA INCINVAHealth Care
A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease…
$21.43 (as of 2026-07-22) · market cap $1.6B
-
ENANTA PHARMACEUTICALS INCENTAHealth Care
A biotechnology company leveraging small molecule discovery to treat viral and liver diseases, supported by recurring HCV royalty streams.
$13.06 (as of 2026-07-22) · market cap $390M
-
XOMA ROYALTY CORPXOMAHealth Care
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights…
$40.17 (as of 2026-07-21) · market cap $710M
-
RevvityRVTYHealth Care
Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic…
$110.54 (as of 2026-07-22) · market cap $12.3B
-
ZYMEWORKS INCZYMEHealth Care
A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation…
$23.36 (as of 2026-07-22) · market cap $1.7B
-
ACHIEVE LIFE SCIENCES INCACHVHealth Care
A clinical-stage biotech developing cytisinicline for smoking cessation and nicotine dependence, preparing for commercialization after completing key clinical…
$6.31 (as of 2026-07-22) · market cap $646M
-
HalozymeHALOHealth Care
Halozyme monetizes its patented hyaluronidase enzyme and microparticle drug delivery technologies through partnerships with major pharma, earning milestone…
$77.82 (as of 2026-07-22) · market cap $9.3B
-
SELLAS LIFE SCIENCES GROUP INCSLSHealth Care
SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid…
$12.08 (as of 2026-07-22) · market cap $2.2B
-
IQVIAIQVHealth Care
IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2…
$198.52 (as of 2026-07-22) · market cap $33.2B
Not quite? Describe exactly what you want →
Peers are Royalty Pharma's closest public companies by shared sub-industry, sector and business themes. See the full profile: Royalty Pharma (RPRX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.